TELA Stock — Tela Bio Inc

Tela Bio Inc (TELA)

Updated October 16, 2026.

TELA is a Stock. Total return is -92.7% over the past 6.9 years, 265.8 points behind SPY at 173.1%.

Tela Bio is a commercial-stage medical technology company that develops soft-tissue reconstruction products for hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. The company markets its OviTex Reinforced Tissue Matrix products—derived from ovine rumen combined with synthetic polymers—through a direct sales force primarily in the United States. The company does not currently distribute to shareholders.

TELA performance versus SPY

Price and return data through 2026-10-16.

Total return is -92.7% over the past 6.9 years, 265.8 points behind SPY at 173.1%. Over the past year its total return — price change plus distributions reinvested — is -35.0%. Its deepest 1-year drawdown was 63.4%.

TELA key facts

Asset type

Stock

Asset class

Equity

Inception date

11/08/2019

Distribution frequency

None

Last close

$0.97 (as of 2026-10-16)

Market cap

$44,014,825

Average volume

164748.0

Beta

1.36

Payout ratio

0.0%

EPS

$-0.77

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

TELA risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 63.4%.

Who may consider TELA — and who may not

It is a weaker fit for investors who need monthly cash flow (TELA does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on TELA

• All tickers starting with T

Tagged: Healthcare.

Frequently asked questions